ReviewCancers2026
The Immune Landscape of Chondrosarcoma: A Review of Tumor-Related Immune Cells.
Review in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Chondrosarcoma (CS) is a rare cancer comprising a heterogeneous group of malignant cartilage-forming tumors. CS is considered a "surgical disease" characterized by high levels of resistance to chemotherapy, radiation therapy, and limited response to immune checkpoint inhibitors. Due to the rarity of the disease and lack of research models, the impact of the CS microenvironment on tumor development and progression remains elusive. Nevertheless, a few recent studies have begun to interpret the composition and function of the CS tumor immune microenvironment (TME), elucidating its contribution to immune evasion and tumor progression. This review summarizes current findings on the immune cell landscape of CS, highlighting key immune cells, their characteristics, and their potential as therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.